HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ICCR Ushers Forth Updated Cosmetic GMP Guidelines From FDA

This article was originally published in The Rose Sheet

Executive Summary

FDA’s draft revision of Cosmetic Good Manufacturing Practices takes into account international consensus formed through harmonization efforts under the International Cooperation on Cosmetics Regulations, says the agency. The recommendations update guidelines created in 1997 and revised in 2008.

You may also be interested in...

MoCRA Confidentiality For AE Reports? And Other Questions Raised At IBA Regulatory Forum

Independent Beauty Association president and CEO Don Frey, Kerry Tassopoulos of Platt Cheema Richmond PLLC, and IBA board member and Co-CEO and president Craig Weiss of the Consumer Product Testing Company fielded questions on MoCRA implementation at IBA’s 2023 Technical/Regulatory Forum.

FDA Targets Spring 2019 For Cosmetics Manufacturing Survey; PCPC Input Taken

From the Personal Care Products Council’s standpoint, FDA’s planned survey of current manufacturing practices in the cosmetics sector isn’t necessary, but the group provided input to contractor RTI to help develop the instrument for optimal utility. Pending OMB approval, FDA aims to launch the survey in spring 2019.

Keystone Labs Court-Ordered To Halt OTC Drug Manufacturing; Cosmetics Not Affected, It Says

Keystone Labs agrees to cease manufacturing OTC drugs following a 2013 FDA warning letter and repeated GMP violations noted during inspections, including failure to investigate sources of contamination. Firm suggests it will continue making cosmetic hair- and skin-care formulas while outsourcing OTC product manufacturing.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts